Diagnostics; making a difference

Member Press Releases

Current Articles | Categories | Search | Syndication

03 January 2017  Joanne Hunter
By Joanne Hunter @ 11:05 :: 65 Views

Mologic is pleased to announce that we are in receipt of a grant from the <strong;>Bill & Melinda Gates Foundation to establish the CARD, a new technology centre within Mologic, whose objective is to create a step-change in simple, rapid diagnostic test technology for the detection of protein biomarkers at the point-of care.

Read More

15 December 2016  Joanne Hunter
OGT expands Cytocell sarcoma FISH probe range
By Joanne Hunter @ 15:11 :: 82 Views

Oxford, UK – 15 December 2016.
Oxford Gene Technology (OGT), The Molecular Genetics Company, has expanded its range of Cytocell Aquarius® fluorescence in situ hybridisation (FISH) probes for pathology. OGT has introduced three new probes: FUS Breakapart and FOXO1 Breakapart, both carrying the CE-IVD label – and TFE3 Breakapart, for research use only. This expansion reinforces OGT’s commitment to providing the most comprehensive and up-to-date range available, facilitating cancer research and diagnosis.

Read More

13 December 2016  Joanne Hunter
New data demonstrate that Oncotype DX® can help guide treatment decisions before breast cancer surgery enabling more personalised care, including avoidance of full mastectomy
By Joanne Hunter @ 10:01 :: 87 Views

LONDON, [December 12, 2016] – New data presented at the 2016 San Antonio Breast Cancer Symposium (SABCS) demonstrate that analysing tumor biology with the Oncotype DX test can identify patients unlikely to benefit from chemotherapy prior to breast cancer surgery (neoadjuvant setting) and guide treatment decisions without compromising outcomes.[1]

[1] Bear H.D. et al. Using the 21gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial. San Antonio Breast Cancer Symposium. December 2016. 

Read More

09 December 2016  Joanne Hunter
BBI Solutions launches a new enzyme for Urinalysis
By Joanne Hunter @ 09:17 :: 93 Views

BBI Solutions (BBI) today announced the launch of Porcine Liver Esterase (PLE), a new enzyme for Urinalysis, which is available to sample now.

Read More

09 December 2016  Joanne Hunter
OGT releases targeted NGS panel to study SNV and CNV in Familial Hypercholesterolemia
By Joanne Hunter @ 09:03 :: 87 Views

Oxford, UK – 08 December 2016.
Oxford Gene Technology (OGT), The Molecular Genetics Company, has expanded its customisable SureSeq™ NGS panel range with the launch of the SureSeq myPanel™ NGS Custom FH Panel – allowing fast and cost-effective study of variants in familial hypercholesterolemia (FH). The new panel delivers both single nucleotide variation (SNV) and copy number variation (CNV) detection on a single small NGS panel assay and allows customisation by ‘mix and match’ of fully-tested and optimised gene and hotspot content. This includes all exons for LDLR, PCSK9, APOB, LDLRAP1, APOE, LIPA and STAP1 and a further 14 single-nucleotide polymorphisms (SNPs). This enables researchers to selectively sequence relevant regions, increasing throughput and saving on reagents.

Read More

02 December 2016  Joanne Hunter
QuantuMDx receives grant funding from Gates Foundation for diagnostic to reach the missing 4.3 million TB cases a year
By Joanne Hunter @ 09:30 :: 106 Views

28th November 2016, Newcastle upon Tyne, UK. QuantuMDx announced today that it received funding from the Bill & Melinda Gates Foundation to further develop and test its CAPTURE-XT™ pathogen concentration technology and Q-POC™ molecular diagnostic (MDx) platform for rapid low cost TB detection and drug susceptibility testing (DST) in response to World Health Organisation target product profiles. The technology is being developed for introduction into peripheral microscopy centres, clinics and hospitals in high burden countries, finally providing a low cost MDx solution to reach the 4.3 million people with TB who are ‘missed’ by healthcare systems each year.

Read More

02 December 2016  Joanne Hunter
Cytox presentations on studies with breakthrough genetic biomarker research assay for Alzheimer’s disease risk assessment at CTAD 2016
By Joanne Hunter @ 09:12 :: 104 Views

1st December 2016
, Oxford, UK. Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, has announced that it will be presenting two posters at the Clinical Trials on Alzheimer’s Disease Conference, CTAD 2016, San Diego, USA, December 8-10th, discussing SNP (single nucleotide polymorphism) profiling and the use of polygenic risk score algorithms for stratification of early subjects for risk of Alzheimer's disease (AD).

Read More

29 November 2016  Joanne Hunter
Beckman Coulter announces significant investment in UK microbiology market with DxN VERIS Molecular Diagnostics and MicroScan Microbiology Systems
By Joanne Hunter @ 11:01 :: 99 Views

High Wycombe, UK, 29 November 2016: Beckman Coulter has launched two automated systems in the UK to ease rapidly increasing workloads in microbiology and virology departments. The DxN VERIS Molecular Diagnostics system, for same-day molecular viral load testing, and the MicroScan Microbiology Systems for microorganism identification (ID) and antimicrobial susceptibility testing (AST), both rapidly and accurately identify therapeutic pathways for patient management. This high-throughput testing significantly streamlines laboratory workflows, and reduces time to patient therapy diagnoses. The launch marks the advent of a significant investment in the UK microbiology market by Beckman Coulter with further product introductions scheduled.

Read More

22 November 2016  Joanne Hunter
OGT announces commercial and financial highlights for FY 2016
By Joanne Hunter @ 14:19 :: 118 Views

Oxford, UK – 22 November 2016. Oxford Gene Technology (OGT), The Molecular Genetics Company has announced continued strong sales of its highly integrated molecular genetics product portfolio, delivering sustainable, profitable growth. Commercial and financial highlights for the year ended 30 September show the company delivering product sales of £18.4m, up 29% on FY 2015.

  • Total revenue grew by 15% to £19.7m (FY2015: £17.1m)
  • Product revenues grew 29% to £18.4m (FY2015: £14.3m)
  • Fully integrated portfolio delivers sustainable profitable growth
Read More

07 November 2016  Joanne Hunter
By Joanne Hunter @ 12:25 :: 152 Views

ELITechGroup Molecular Diagnostics announce today the CE-IVD marking of the CRE ELITe MGB® Assay, a high-performance, qualitative, multiplex assay for the rapid detection of the Carbapenem Resistance genes of Enterobacteriaceae. In combination with the ELITe InGenius™, the ELITech Group’s fully automated sample-to-result system, the assay is intended to detect 150 variants belonging to the 5 main families of Carbapenem-Resistant genes: KPC, NDM, VIM, IMP, and OXA-48 like and differentiate the main classes.

Read More

Previous Page | Next Page